NRx Pharmaceuticals, Inc. (NRXP)
NASDAQ: NRXP · Real-Time Price · USD
2.190
-0.190 (-7.98%)
At close: Mar 27, 2026, 4:00 PM EDT
2.120
-0.070 (-3.20%)
After-hours: Mar 27, 2026, 7:59 PM EDT
NRx Pharmaceuticals Revenue
In the year 2025, NRx Pharmaceuticals had annual revenue of $1.23M. NRx Pharmaceuticals had revenue of $983.00K in the quarter ending December 31, 2025.
Revenue (ttm)
$1.23M
Revenue Growth
n/a
P/S Ratio
59.06
Revenue / Employee
n/a
Employees
n/a
Market Cap
72.35M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.23M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Verrica Pharmaceuticals | 35.58M |
| Pelthos Therapeutics | 16.80M |
| NeurAxis | 3.57M |
| Kazia Therapeutics | 1.27M |
| aTyr Pharma | 190.00K |
NRXP News
- 5 days ago - NRx Pharmaceuticals, Inc. (NRXP) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress - GlobeNewsWire
- 6 days ago - NRx Pharmaceuticals, Inc. (NRXP) Shareholder/Analyst Call Prepared Remarks Transcript - Seeking Alpha
- 10 days ago - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026 - GlobeNewsWire
- 12 days ago - NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx's Preservative-Free Ketamine Application - GlobeNewsWire
- 13 days ago - NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting - GlobeNewsWire
- 20 days ago - HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD - GlobeNewsWire
- 27 days ago - NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer - GlobeNewsWire